Australian MS patients who took part in a pioneering trial of autologous Epstein Barr virus-specific T cell therapy have shown clinical improvements that have been maintained for up to three years. In 2015, 10 patients with progressive MS took part in a phase 1 clinical trial of autologous EBV-specific T cell therapy in Queensland. The ...
MS patients show sustained response after EBV immunotherapy: Queensland study
By Michael Woodhead
20 May 2021